Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
· anteris technologies pty ltd
AI Briefing
- Anteris Technologies secures CMS reimbursement supporting U.S. site activation for the global pivotal PARADIGM Trial evaluating the DurAVR THV.
- This development marks a significant milestone for the company's U.S. launch efforts.
- The PARADIGM Trial is designed to assess the safety and efficacy of the DurAVR THV in treating heart failure patients.
Advertisement